Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

NCT06263543 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

75

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Metastatic Breast Cancer
Advanced Breast Cancer
Hormone-receptor-positive Breast Cancer
Human Epidermal Growth Factor 2 Low Breast Cancer

Interventions

DRUG: Sacituzumab govitecan

Sponsor

Reshma L. Mahtani, D.O.

Collaborators

[object Object]